SAN JOSE, Calif., Aug. 14 /PRNewswire-FirstCall/ -- Applied Imaging Corp. , today announced financial and operating results for the second quarter ended June 30, 2006.
Total revenues for the second quarter of 2006 were $5.0 million, up from $4.9 million in the second quarter of 2005. Total revenues for the six months ended June 30, 2006 were $9.9 million, up from $9.8 million in the same period last year.
The Company incurred a net loss of $310,000, or $(0.06) per share, as compared to a net loss of $436,000, or $(0.09) in the second quarter of 2005. The second quarter 2006 net loss included a $135,000 charge for the expensing of stock options related to the adoption of SFAS 123R in the first quarter of 2006. Excluding this stock option expense, non-GAAP net loss for the second quarter would have been $175,000 or $(0.04) per share. The Company also decreased its net loss for the six months ended June 30, 2006 by 61% to $372,000, or $(0.07) per share, compared to a net loss of $947,000, or $(0.20) per share, for the same period last year. Net loss for the six months ended June 30, 2006 included a $295,000 charge for the expensing of stock options in relation to SFAS 123R. Excluding this stock option expense, non-GAAP net loss for the six months ended June 30, 2006 would have been $77,000, or $(0.01) per share. A reconciliation of GAAP and non-GAAP operating results is provided below.
Gross profit for the quarter rose to $3.3 million, compared to $2.9 million in the same period in 2005. Gross margin for the quarter was 65%, up from 59% in the second quarter in 2005. Gross profit also improved from $3.0 million, or 61% of revenues, in the first quarter of 2006. For the six-month period ended June 30, 2006, gross profit increased by 9% to $6.3 million, from $5.8 million in the same period last year. Gross margin for the six-month period ended June 30, 2006 was 63%, versus 59% for the same period last year.
Operating expenses were $3.7 million, up from $3.2 million in the second quarter of 2005, and included a $129,000 charge for the expensing of stock options as well as $720,000 in expenses associated with the Company's retention bonus program announced in December 2005. Excluding the impact of the stock option and retention bonus expenses, non-GAAP operating expenses for the second quarter of 2006 would have been $2.8 million, a 12% decrease from the comparable period in 2005. Operating expenses for the six-month period ended June 30, 2006 were $6.7 million, down from $6.5 million for the comparable 2005 period, and included a $273,000 charge for the expensing of stock options, as well as above mentioned $720,000 retention bonus program charge. Excluding the impact of the stock option and retention bonus expenses, non-GAAP operating expenses for the six-month period ended June 30, 2006, would have been $5.7 million, a 13% decrease from the comparable period in 2005.
Commenting on the second quarter results, Applied Imaging's President and CEO, Robin Stracey, said, "In the second quarter, revenues met our expectations as our CytoVision(R) family of products continued its solid performance in the U.S. and Europe. We had our first placements of Ariol(R) in China and Australia, and business remained strong in the U.K. We remained vigilant in our cost-cutting initiatives and as a result, margins improved and our operating loss was lower than anticipated." Mr. Stracey added, "Our CTC unit continued its efforts and progressed to patient sample testing and validation with the preferred enrichment method, after having completed initial validation work with spiked samples."
As of June 30, 2006, the Company had cash and cash equivalents of $3.3, up from $3.1 million as of December 31, 2005. Working capital totaled $635,000 as of June 30, 2006, compared to $(494,000) as of December 31, 2005.
For fiscal 2006, the Company reaffirms its expectation that revenues will be approximately $21.0 million. The Company anticipates sustaining profitability in its core imaging business and continuing investment in its CTC, Inc. subsidiary.
Use of Non-GAAP Financial Measures
Effective January 1, 2006, the Company adopted Statement of Financial Accounting Standards (SFAS) No. 123(R), which requires the Company to begin recognizing compensation expense relating to stock-based payment transactions. To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, the Company provides non-GAAP financial information. The Company's management believes that these non-GAAP measures provide investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of adjustments to GAAP results for the quarter ended June 30, 2006 is included below. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that we provide also may differ from the non-GAAP information provided by other companies.
Applied Imaging Corp. will host a conference call today, Monday, August 14, 2006, at 8:00 a.m. PT (11:00 a.m. ET) to discuss results for the second quarter of 2006. Joining Robin Stracey, President and CEO of Applied Imaging Corp. will be Terry Griffin, Chief Financial Officer, and VP of Strategy and Business Development, Bill Cook. To participate in the conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (877) 586-7724. International callers should dial 001 (706) 679-0614. The conference ID number is 4084241. If you are unable to participate in the call at this time, a replay will be available on Monday, August 14 at 12:00 p.m. ET, through Monday, August 21 at midnight ET. To access the replay dial (800) 642-1687 and enter the conference ID number 4084241. International callers should dial 001 (706) 679-0614 with the same conference ID number.
About Applied Imaging
Applied Imaging Corp., based in San Jose, California, is the leading supplier of automated imaging and image analysis systems for the detection and characterization of chromosomes and molecular markers in genetics and cancer applications. The Company markets a wide range of imaging and image analysis systems for fluorescence and brightfield microscopy, including the Company's Ariol(R) and CytoVision(R) product families. Applied Imaging has installed over 4,000 systems in over 1,000 laboratories in more than 60 countries. The Company is also developing a system for the detection, quantification and characterization of circulating tumor cells from the blood of cancer patients. More information about Applied Imaging can be found at http://www.aicorp.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward looking statements as defined in the Private Securities Litigation Reform Act of 1995, regarding, among other matters, the ability of the Company to select and optimize a protocol for concentrating tumor cells; the Company's expectations regarding the extent and nature of expenses to be incurred in research and development, sales and marketing, general and administrative and for its CTC, Inc. subsidiary; the Company's ability to achieve its anticipated revenues in 2006, to sustain profitability in its core imaging business, and to continue investment in its CTC, Inc. subsidiary; and its financial guidance for 2006. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of factors, including those factors as set forth in Applied Imaging's most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. The forward-looking statements in this news release are made as of August 14, 2006, and Applied Imaging is under no obligation to revise or update these forward-looking statements.
For More Information:
CCG Investor Relations
Crocker Coulson, President
10960 Wilshire Boulevard, Suite 2050
Los Angeles, CA 90024
Applied Imaging Corp.
Terry Griffin, Chief Financial Officer
120 Baytech Drive,
San Jose, CA 95134
- Financial Tables Follow -
Applied Imaging Corp. and Subsidiaries
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except per share data)
Three Months ended Six Months ended
June 30, June 30,
2006 2005 2006 2005
Revenues $5,032 $4,912 $9,898 $9,802
Cost of revenues(a) 1,744 2,015 3,637 4,039
Gross profit 3,288 2,897 6,261 5,763
Research and development(a) 755 870 1,501 1,755
Sales and marketing(a) 1,537 1,323 2,906 2,721
General and administrative(a) 1,364 1,013 2,257 2,066
Total operating expenses 3,656 3,206 6,664 6,542
Operating loss (368) (309) (403) (779)
Other income/(expense) 58 (127) 31 (168)
Net loss $(310) $(436) $(372) $(947)
Net loss per share - basic and
diluted(b) $(0.06) $(0.09) $(0.07) $(0.20)
Weighted average shares outstanding
- basic and diluted(c) 5,589 4,776 5,270 4,780
(a)Stock compensation expense was
allocated as follows:
Cost of Revenues $6 $22
Research and development 30 77
Sales and marketing 21 41
General and administrative 78 155
Total stock compensation
expense $135 $295
(b) Prior to January 1, 2006, the Company accounted for stock
compensation under Accounting Principles Board, Opinion No. 25, "
Accounting for Stock Issued to Employees" ("APB 25"). In accordance
this APB 25, the Company used the intrinsic value method to account
to stock compensation expense. As of January 1, 2006 the Company
accounts for stock compensation expense under the fair value method.
As the Company adopted the modified prospective transition method,
results of the prior period have not been restated under the fair
valued method for GAAP purposes. The Company previously applied APB
25 and related interpretations and provided the required pro forma
disclosures of SFAS No. 123, "Accounting for Stock-Based
(c) All share and per share common stock information in this Press
Release reflects a 1-for-4 reverse stock split of the common stock
effected May 20, 2005.
Selected Consolidated Balance Sheets Data
(Unaudited, in thousands)
June 30, December 31,
Cash and cash equivalents $3,321 $3,136
Restricted cash $164 $172
Working capital $634 $(494)
Total assets $11,957 $12,528
Total stockholders' equity $3,372 $2,353
Note: Selected financial information. Please see the appropriate Company reports on Forms 10-Q and 10-K as filed with the Securities and Exchange Commission for complete financial information and Notes.
Reconciliation of GAAP Net Loss and Loss Per Share to Non-GAAP Net Income
and Earnings Per Share
(Unaudited, in thousands, except per share data)
Three Months Ended Six Months Ended
June 30, June 30,
GAAP net loss $(310) $(372)
Stock-based compensation 135 295
Non-GAAP net income $(175) $(77)
GAAP loss per share $(0.06) $(0.07)
Stock-based compensation 0.02 0.06
Non-GAAP earnings per share - basic $(0.04) $(0.01)
Weighted average shares outstanding -
basic(b) 5,589 5,270
Applied Imaging Corp.